“
“Background Mother-to-child transmission (MTCT) of hepatitis B virus(HBV)

still remains a world concerned question. Previous studies have demonstrated the effectiveness of telbivudine (LdT) and lamivudine (LAM) in pregnancy, but there were few data about tenofovir (TDF), also it is a controversal problem on the GW-572016 solubility dmso choice of antiviral drugs and the appropriate time to start therapy. Purpose To evaluate the safety and reliability of tenofovir in preventing mother-to-child transmission of HBV during pregnancy. Methods We totally enrolled 38 HBV infected pregnant women with HBsAg and HBeAg positive since 8/2009 until 5/2013. Among these patients, 21 women were treated with TDF (300mg/d) alone; 11 were treated with TDF (300mg/d) +LDT (600mg/d), while 6 were treated with TDF (300mg/d)

+LAM (100mg/d) during pregnancy. All the babies were injected with hepatitis B vaccine and immunoglobulin according to the standard protocal after birth. Mothers co-infected with other liver diseases were excluded from the study. Results In our study, 13 mothers started treatment at the first trimester (0-11 weeks); and 4 began treatment at PLX4032 ic50 the second trimester (15-24 weeks); while 21 started treatment at the third trimester (28-39 weeks). Five mothers were with ALT elevation before treatment which ranged from 1.8×ULN to 12.2×ULN and 2 of them decreased to normal level at delivery. All the infants cordblood were detected negative for HBV DNA and born with no congenital diseases. All babies were detected negative for HBsAg and HBV DNA at 20-48 weeks . Conclusion It is safe and effective by using tenofovir MCE公司 in prevent mother-to-child transmission of HBV during the whole pregnancy. Disclosures: The following people have nothing to disclose: Hongfei Huang, Quanxin Wu, Yuming Wang

Background: AASLD treatment guideline for CHB recommends ALT ≥ two times the upper limit of normal (ULN) as one of the major criteria to initiate antiviral therapy. However, patients with ALT < 2× ULN may not be free from future risk of liver complications such as hepatocellular carcinoma (HCC). Our aim is to compare the risk of HCC for non-cirrhotic CHB patients by an ALT levels and by treatment status. Method: We performed a retrospective cohort study of 1814 consecutive treatment-naïve, noncirrhotic CHB patients aged 40 or older whose follow-up was 12 months or longer from 1991-2014 at four U.S. medical clinics. ALT of ≥2× ULN was defined by gender (≥60 for men, ≥ 38 for women). Survival analysis with Kaplan Meier curves were produced to capture the rate of HCC development by ALT level and in those who were treated versus those who remained untreated. Annual incidence was reported in cases per 1000 person-years. Results: The majority of patients were males (59%), had HBeAg-negative status (85%), and had a mean age of 52.5 ± 9.8. Median years of follow-up was 4 (1-10) years.